Institute of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Pancreas. 2011 Jul;40(5):669-72. doi: 10.1097/MPA.0b013e31821fd5cd.
The aim of this study was to investigate whether the use of statins was associated with pancreatic cancer risk.
We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National health Insurance Research Database. Cases consisted of all patients who were 50 years or older and had a first-time diagnosis of pancreatic cancer for the period between 2003 and 2008. The control subjects were matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multiple logistic regression.
We examined 190 pancreatic cancer cases and 760 control subjects. The unadjusted OR for any statin prescription was 1.07 (95% CI, 0.72-2.06), and the adjusted OR was 0.87 (95% CI, 0.56-1.36). Compared with no use of statins, the adjusted ORs were 1.06 (95% CI, 0.61-1.85) for the group having been prescribed statins with cumulative defined daily doses less than 114.33 and 0.71 (95% CI, 0.39-1.30) for the group with cumulative statin use of 114.33 defined daily doses or more.
This study does not provide support for a beneficial association between usage of statin and pancreatic cancer.
本研究旨在探讨他汀类药物的使用与胰腺癌风险之间的关系。
我们在台湾进行了一项基于人群的病例对照研究。数据是从台湾全民健康保险研究数据库中回顾性收集的。病例组由 2003 年至 2008 年间首次诊断为胰腺癌且年龄在 50 岁或以上的所有患者组成。对照组与病例组按年龄、性别和索引日期相匹配。采用多因素 logistic 回归估计调整后的比值比（OR）和 95%置信区间（CI）。
我们共纳入了 190 例胰腺癌病例和 760 例对照。未调整的任何他汀类药物处方的 OR 为 1.07（95%CI，0.72-2.06），调整后的 OR 为 0.87（95%CI，0.56-1.36）。与未使用他汀类药物相比，累积定义日剂量小于 114.33 的他汀类药物处方组的调整 OR 为 1.06（95%CI，0.61-1.85），累积他汀类药物使用剂量为 114.33 定义日剂量或更多的组的调整 OR 为 0.71（95%CI，0.39-1.30）。
本研究结果不支持他汀类药物使用与胰腺癌之间存在有益关联。
